|
EQS-Ad-hoc: Merck KGaA / Key word(s): Study results Darmstadt, 5 December 2023: Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton’s tyrosine kinase inhibitor (BTKi) as a potential treatment for relapsing multiple sclerosis ("RMS") in two pivotal phase III clinical trials (evolutionRMS 1 and evolutionRMS 2, together the "Clinical Trials"). Both Clinical Trials, evaluating the efficacy and safety of evobrutinib compared to teriflunomide for up to 156 weeks, did not meet the primary endpoint of reducing annualized relapse rates (ARR) in people with RMS.
Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world. Contact: Esther Döringer Merck KGaA Frankfurter Straße 250 64293 Darmstadt Germany Phone: +49 151 1454 7809 Email: esther.doeringer@merckgroup.com Internet: https://www.merckgroup.com/en ISIN: DE0006599905 WKN: 659990 Indices: DAX Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX End of Inside Information
05-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Merck KGaA |
| Frankfurter Str. 250 | |
| 64293 Darmstadt | |
| Germany | |
| Phone: | +49 (0)6151 72 - 2702 |
| E-mail: | Friederike.Segeberg@merckgroup.com |
| Internet: | https://www.merckgroup.com/de |
| ISIN: | DE0006599905 |
| WKN: | 659990 |
| Indices: | DAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX |
| EQS News ID: | 1790011 |
| End of Announcement | EQS News Service |
|
|
1790011 05-Dec-2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
